{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=antibody-drug+conjugate&page=21", "query": { "intervention": "antibody-drug conjugate", "page": 21 }, "page_size": 10 }, "pagination": { "page": 21, "page_size": 10, "total_count": 499, "total_pages": 50, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=antibody-drug+conjugate&page=22&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=antibody-drug+conjugate&page=20&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T17:35:46.800Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03729596", "title": "MGC018 With or Without MGA012 in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of Head and Neck", "Triple Negative Breast Cancer", "Melanoma", "Advanced Solid Tumor, Adult", "Metastatic Castrate Resistant Prostate Cancer", "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "vobramitamab duocarmazine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 143, "start_date": "2018-11-21", "completion_date": "2023-03-18", "has_results": true, "last_update_posted_date": "2025-07-31", "last_synced_at": "2026-10-15T17:35:46.800Z", "location_count": 9, "location_summary": "Santa Monica, California • Washington D.C., District of Columbia • Baltimore, Maryland + 5 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03729596" }, { "nct_id": "NCT07529808", "title": "Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastric Cancer", "Gastric Adenocarcinoma", "Gastric (Stomach) Cancer", "Gastroesophageal Adenocarcinoma", "Gastroesophageal Cancer (GC)", "Gastroesophageal Junction (GEJ) Adenocarcinoma", "Gastroesophageal Junction (GEJ) Cancer", "Gastrointestinal Cancer Metastatic", "Gastrointestinal Adenocarcinoma", "Gastrointestinal Cancers", "Colorectal (Colon or Rectal) Cancer", "Pancreatic Cancer", "CDH17-positive Advanced Solid Tumors", "Advanced Gastric Cancer" ], "interventions": [ { "name": "BHB810", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BigHat Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 164, "start_date": "2026-07-16", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-15T17:35:46.800Z", "location_count": 3, "location_summary": "Duarte, California • Santa Monica, California • Fairfax, Virginia", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07529808" }, { "nct_id": "NCT04784715", "title": "Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer; HER2-positive; Metastatic" ], "interventions": [ { "name": "Trastuzumab deruxtecan", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Taxane", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 1157, "start_date": "2021-04-26", "completion_date": "2029-12-30", "has_results": false, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-10-15T17:35:46.800Z", "location_count": 30, "location_summary": "Tucson, Arizona • Springdale, Arkansas • Glendale, California + 25 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Glendale", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Longmont", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04784715" }, { "nct_id": "NCT03510208", "title": "Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Malignant Brain Neoplasm", "Malignant Glioma" ], "interventions": [ { "name": "Near-Infrared Fluorescence Imaging", "type": "PROCEDURE" }, { "name": "Panitumumab", "type": "BIOLOGICAL" }, { "name": "Panitumumab-IRDye800", "type": "DRUG" }, { "name": "POINPOINT-IR9000", "type": "DEVICE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG", "DEVICE" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2018-05-16", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2026-06-29", "last_synced_at": "2026-10-15T17:35:46.800Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03510208" }, { "nct_id": "NCT04745949", "title": "PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Lymphoma" ], "interventions": [ { "name": "Brentuximab Vedotin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2021-05-10", "completion_date": "2027-08-03", "has_results": false, "last_update_posted_date": "2026-02-19", "last_synced_at": "2026-10-15T17:35:46.800Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04745949" }, { "nct_id": "NCT06980506", "title": "MNPR-101-DFO*-89Zr Expanded Access Program (EAP) for Patients With Solid Tumor Cancer", "overall_status": "TEMPORARILY_NOT_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Cancer", "Solid Tumor", "Solid Tumor, Adult" ], "interventions": [ { "name": "MNPR-101-DFO*-89Zr", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Monopar Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-10-15T17:35:46.800Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06980506" }, { "nct_id": "NCT01026233", "title": "Cardiac Safety Study of Brentuximab Vedotin (SGN-35)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Disease, Hodgkin", "Lymphoma, Large-Cell, Anaplastic", "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "brentuximab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2010-01", "completion_date": "2011-08", "has_results": false, "last_update_posted_date": "2014-12-12", "last_synced_at": "2026-10-15T17:35:46.800Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Duarte, California • Stanford, California + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Maywood", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01026233" }, { "nct_id": "NCT07090499", "title": "A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced/Metastatic Solid Tumors", "Bladder Cancer", "Urothelial Carcinoma", "Advanced Non-Small Cell Lung Cancer", "Carcinoma, Non Small Cell Lung", "Carcinoma, Squamous Cell of Head and Neck", "Head and Neck Cancer", "Esophageal Cancer", "Gastroesophageal Junction Adenocarcinoma", "Esophageal Squamous Cell Carcinoma", "Esophageal Adenocarcinoma", "Pancreatic Adenocarcinoma", "Pancreatic Cancer" ], "interventions": [ { "name": "PF-08046876", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "COMBINATION_PRODUCT" }, { "name": "Cisplatin", "type": "COMBINATION_PRODUCT" }, { "name": "Carboplatin", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 540, "start_date": "2025-08-20", "completion_date": "2029-07-08", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-15T17:35:46.800Z", "location_count": 21, "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 11 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07090499" }, { "nct_id": "NCT07484022", "title": "Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Urothelial Cancer", "Metastatic Urothelial Carcinoma" ], "interventions": [ { "name": "GB-4362", "type": "DRUG" }, { "name": "enfortumab vedotin (EV)", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Generate Biomedicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2026-06-08", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-15T17:35:46.800Z", "location_count": 10, "location_summary": "Duarte, California • Irvine, California • Orlando, Florida + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tucker", "state": "Georgia" }, { "city": "Zion", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07484022" }, { "nct_id": "NCT06400472", "title": "A Study of Sofe-M in Participants With Selected Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Neoplasms", "Endometrial Neoplasms", "Uterine Cervical Neoplasms", "Carcinoma, Non-Small-Cell Lung", "Triple Negative Breast Neoplasms", "Pancreatic Neoplasm", "Colorectal Neoplasms" ], "interventions": [ { "name": "Sofe-M", "type": "DRUG" }, { "name": "bevacizumab", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 575, "start_date": "2024-05-20", "completion_date": "2029-06", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-15T17:35:46.800Z", "location_count": 11, "location_summary": "Scottsdale, Arizona • La Jolla, California • Atlanta, Georgia + 7 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Mineola", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06400472" } ] }